Aetion
Aetion provides a proprietary Evidence Platform for real-world evidence generation, serving major biopharma companies in drug development, clinical trials, and regulatory submissions. The platform uses generative AI on AWS Bedrock and was acquired by Datavant in May 2025.
- Company typePrivate
- Founded2013
- HeadquartersNew York, United States
- Headcount251–500
- GTM typeB2B
- OfferingSoftware
What Aetion does
Aetion is a New York-based healthcare technology company founded in 2013 that provides real-world evidence (RWE) and outcomes-based analytics solutions to life sciences companies. Its core product is the Aetion Evidence Platform, a proprietary system that analyzes real-world data (RWD) to support drug development, clinical trial analysis, personalized medicine, and regulatory submissions for major biopharma customers worldwide. The platform leverages generative AI built on Amazon Bedrock to translate scientific intent into analytical results, and in August 2025 the company launched aetion activate, an accelerated RWD analysis module. Aetion operates a subscription-based SaaS revenue model distributed through direct enterprise sales to biopharma customers, with the Evidence Platform also made available on AWS Marketplace in March 2025 to broaden cloud-native procurement.
Aetion's customer base is concentrated in major biopharma enterprises, and the company reported near-100% customer renewals with revenue nearly doubling in the year preceding its May 2021 $110 million Series C led by Warburg Pincus. In February 2025, NEC Orchestrating Future Fund made a strategic investment and began collaboration discussions to apply Japanese electronic health records to drug development. In May 2025, Datavant announced its acquisition of Aetion to combine Aetion's RWE capabilities with Datavant's data discovery, linkage, privacy, and analytics infrastructure into an end-to-end RWE platform. Following the acquisition, Aetion operates as part of Datavant's life sciences offerings and is no longer an independent entity.
Aetion firmographics
Firmographics- Name
- Aetion
- Legal name
- Aetion, Inc.
- Website
- https://aetion.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Short description
- Aetion provides a proprietary Evidence Platform for real-world evidence generation, serving major biopharma companies in drug development, clinical trials, and regulatory submissions. The platform uses generative AI on AWS Bedrock and was acquired by Datavant in May 2025.
- Ownership category
- akta.pro rank
Aetion industry classification
Industry- Product category
- Healthcare Analytics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN)
- akta.pro secondary industry
- Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM)
Keywords
Where Aetion is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Aetion business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- Evidence Platform SaaS Subscription: Aetion generates revenue through its Evidence Platform which supports real-world evidence generation for biopharma customers. The company showed nearly 100% customer renewals and nearly doubled revenue in the year prior to its 2021 Series C, indicating a recurring subscription model.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels3 records
Aetion product offering
Product offeringCore offering
Aetion develops and sells the Aetion Evidence Platform, a real-world evidence (RWE) analytics software platform used by major biopharma companies to analyze real-world data for drug development, clinical trial design, regulatory submissions, and personalized medicine. The platform leverages generative AI on Amazon Bedrock to translate scientific intent into analytical results, and is sold as enterprise SaaS with an option to procure through AWS Marketplace.
Product overview
Aetion offers a platform-plus-modules architecture centered on its Evidence Platform® for real-world evidence generation. The core platform processes and analyzes real-world data from diverse sources, while aetion activate (launched August 2025) provides accelerated analysis capabilities. The company leverages generative AI via Amazon Bedrock to translate scientific intent into results, serving biopharma companies, healthcare providers, and regulatory bodies seeking to improve drug development efficiency and advance personalized medicine.
Differentiator
Problem solved
Functional benefit
Brands
- Aetion Evidence Platform: Platform supporting real-world evidence generation used by major biopharma companies worldwide
- aetion activate
Products and services
- Aetion Evidence Platform Software platform that enables life sciences companies to analyze real-world data for drug development, clinical trials, regulatory submissions, and personalized medicine, using generative AI to translate scientific intent into analytical results.
- aetion activate Product that accelerates real-world data analysis for pharmaceutical and life sciences companies, designed to generate real-world evidence insights more efficiently from real-world datasets.
Quantifiable outcome
- Nearly 100% customer renewal rate in the year prior to 2021 Series C
- +1 more outcomes
Companies that use Aetion
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Aetion technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Aetion partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered major and core.
- DatavantmajorDatavant announced its acquisition of Aetion in May 2025, aimed at enhancing Datavant's capabilities for life sciences and creating an end-to-end RWE platform. The acquisition combines Aetion's RWE solutions with Datavant's data discovery, linkage, privacy, and advanced analysis capabilities. Following the acquisition, Aetion operates as part of Datavant's platform ecosystem.
- Amazon Web Services (AWS)coreAetion leverages Amazon Bedrock (AWS's generative AI service) to power its Evidence Platform. In March 2025, Aetion also launched the availability of its Evidence Platform in the AWS Marketplace. AWS provides the cloud infrastructure and AI capabilities underlying Aetion's platform, enabling generative AI-driven translation of scientific intent into results.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Aetion competitors and assessment
Company assessmentDirect peers
- Evidera (PPD / Thermo Fisher Scientific): Evidera is a dedicated real-world evidence and health economics consulting business serving biopharma. It is directly comparable to Aetion because both provide RWE generation and outcomes analytics for life sciences customers, often competing for the same budget line within biopharma R&D and HEOR teams.
- Flatiron Health: Flatiron Health is a direct competitor in real-world evidence, focused on oncology EHR-derived data and analytics for biopharma and providers. It is highly comparable to Aetion because both build RWE platforms from real-world clinical data to support drug development and regulatory submissions for life sciences customers.
- TriNetX: TriNetX operates a global health research network and RWE platform for clinical trial design, cohort identification, and real-world evidence studies. It is directly comparable to Aetion because both sell RWE platforms to biopharma for protocol design, regulatory evidence, and clinical development decisions using federated real-world data.
Emerging players
- ConcertAI: ConcertAI provides AI-powered real-world evidence and data solutions with a focus on oncology and specialty therapeutics. It is comparable to Aetion because both serve biopharma with RWE analytics derived from clinical real-world data, competing for similar evidence-generation engagements with major pharma.
- Health Catalyst: Health Catalyst provides healthcare data and analytics infrastructure, including life sciences solutions leveraging clinical and claims data. It is comparable to Aetion because both turn real-world clinical data into analytics products for healthcare stakeholders, though Health Catalyst is more provider-system-anchored while Aetion is biopharma-focused.
- Tempus Labs: Tempus combines multimodal real-world data (omics, EHR, imaging) with AI to support biopharma research and clinical decision-making. It is comparable to Aetion because both build AI-enabled RWE platforms serving biopharma drug development, though Tempus is more focused on oncology and molecular data depth.
- OM1: OM1 is a specialty real-world evidence and outcomes analytics company focused on chronic and specialty disease areas. It is comparable to Aetion because both deliver RWE analytics to biopharma and payers, with similar specialty-therapeutic-area orientation and emphasis on regulatory-grade evidence generation.
Broad incumbents
- ICON plc: ICON (following its PRA Health Sciences acquisition) is a top global CRO with established real-world evidence and outcomes research capabilities. It is comparable to Aetion because both deliver RWE services to biopharma for clinical and post-marketing evidence generation, though ICON operates a much broader CRO service portfolio.
- IQVIA: IQVIA is the largest global CRO and a leading provider of real-world evidence solutions to biopharma. It is comparable to Aetion because both serve major biopharma customers with RWE analytics, though IQVIA operates at vastly greater scale and offers a much broader portfolio spanning clinical trials, commercial, and real-world data.
- Optum Life Sciences (UnitedHealth Group): Optum Life Sciences, part of UnitedHealth Group, provides real-world data and evidence solutions to biopharma leveraging one of the largest U.S. claims and EHR data assets. It is comparable to Aetion because both deliver RWE analytics for biopharma, though Optum's data scale and integrated payer-provider footprint are far larger.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Aetion social profiles
Digital presenceAetion financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aetion leadership team
Management profileNumber of profiles
Profiles14 records
Aetion funding detail
Funding detailFunding overview
Funding rounds7 records
Investors20 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aetion M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aetion
What does Aetion do?
Aetion develops and sells the Aetion Evidence Platform, a real-world evidence (RWE) analytics software platform used by major biopharma companies to analyze real-world data for drug development, clinical trial design, regulatory submissions, and personalized medicine. The platform leverages generative AI on Amazon Bedrock to translate scientific intent into analytical results, and is sold as enterprise SaaS with an option to procure through AWS Marketplace.
Is Aetion a public or private company?
Aetion is a private company. It is classified as corporate owned and is currently acquired.
When was Aetion founded?
Aetion was founded in 2013. It employs 251 to 500 people.
Where is Aetion based?
Aetion is headquartered in New York, United States, in the North America region.
How does Aetion make money?
One revenue line is on record: evidence Platform SaaS Subscription.
Who are Aetion's main competitors?
Direct peers on record are Evidera (PPD / Thermo Fisher Scientific), Flatiron Health and TriNetX. Emerging players are ConcertAI, Health Catalyst, Tempus Labs and OM1. Broad incumbents are ICON plc, IQVIA and Optum Life Sciences (UnitedHealth Group).
Does Aetion have an API?
No public API is recorded for Aetion.
What industry is Aetion in?
Aetion's product category is Healthcare Analytics Software. Its primary akta.pro industry code is BPAHALAN, Healthcare Outcomes & Real-World Evidence (RWE) Analytics, with a secondary code of HLACAOAM, Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms. Its NAICS code is 541714 and its SIC code is 8731.